Skip to content
Screener

Bristol-Myers Squibb BMY Prepaid & Other Current

Prepaid & Other Current at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$4.83B+10.7%
Incyte logo
IncyteINCY
$253.09M-14.4%
Gilead Sciences logo
Gilead SciencesGILD
$3.76B+29.7%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$6.42M+115%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$27.5M-76.9%
Cytokinetics logo
CytokineticsCYTK
$17.99M-10.0%

Other financials

Income statement

See full
Revenue$13.0B+5.7%
Gross profit$9.2B+3.9%
Net income$3.3B+153%
EPS (diluted)$1.62+153%

Balance sheet

See full
Cash & equivalents$8.7B-30.8%
Total debt$43.3B-12.3%
Total equity$22.3B+28.0%
Total assets$87.6B-7.4%

Cash flow

See full
Operating cash flow$3.4B-13.4%
CapEx$305.0M-15.5%
Free cash flow$3.1B-13.2%

Valuation

See full
Market cap$129.98B+42.5%
Enterprise value$164.58B+28.6%
P/E14×-4.3×
P/S2.6×+0.7×

Profitability

See full
Gross margin70.2%-0.1pp
Net margin18.9%+8.4pp
FCF margin23.3%-7.3pp

Returns & leverage

See full
Return on equity46.7%+17.8pp
Debt / equity1.9×-0.9×
Current ratio1.5×+0.3×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsCurrent.

The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 11:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000014272-26-000020
ASSETSJune 30,2026December 31,2025
Marketable debt securities2,345464
Receivables10,55311,414
Inventories2,7372,690
Other current assets4,2224,613
Total Current assets28,57929,390
Property, plant and equipment7,7917,543
Goodwill21,74021,754
Other intangible assets17,38719,103

Item 1. FINANCIAL STATEMENTS

FAQ

What is Bristol-Myers Squibb's prepaid & other current?
Bristol-Myers Squibb (BMY) reported prepaid & other current of $4.22B in Q2 2026.
How has Bristol-Myers Squibb's prepaid & other current changed year-over-year?
Bristol-Myers Squibb's prepaid & other current decreased by 22.8% year-over-year, from $5.47B to $4.22B.
What is the long-term trend for Bristol-Myers Squibb's prepaid & other current?
Over 5 years (2020 to 2025), Bristol-Myers Squibb's prepaid & other current has grown at a 42.4% compound annual growth rate (CAGR), from $787M to $4.61B.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Bristol-Myers Squibb's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude